Basic Information
| LncRNA/CircRNA Name | H19 |
| Synonyms | NA |
| Region | GRCh38_11:1995176-2001470 |
| Ensemble | ENSG00000130600 |
| Refseq | NR_002196 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | Dopaminatic agonists (DAs), including bromocriptine (BRC) and cabergoline(CAB) | ||
| Variant | Cell Growth | Circulating | 2 | ||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | pituitary adenoma |
| ICD-0-3 | C75.1 |
| Methods | qPCR, Western blot |
| Sample | GH3 cell line, pituitary adenoma tissues and plasma exosomes |
| Expression Pattern | down-regulated |
| Function Description | The growth of distal tumor cells was inhibited by transferring exosomal H19, which could be transported through cell membrane and exert its inhibitory effect. Cabergoline increased H19 expression and played a synergic therapeutic effect with exosomal H19. Exosomal H19 inhibited phosphorylation of the mTORC1 substrate 4E-BP1. Of Note, the expression level of exosomal H19 in the patients with all subtypes of pituitary tumors was significantly lower than that in the healthy subjects. The change of plasma exosomal H19 level may be correlated with the prognosis or drug response of the patients. |
| Pubmed ID | 31369093 |
| Year | 2019 |
| Title | Exosome-transmitted lncRNA H19 inhibits the growth of pituitary adenoma |
External Links
| Links for H19 | GenBank HGNC NONCODE |
| Links for pituitary adenoma | OMIM COSMIC |